SCHEMBL1970203

SCHEMBL1970203

Nc1ccc(Oc2ccc3c(c2)S(=O)(=O)NCCN3)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIA2 P42262 8/20 0.40
ALDH1A1 P00352 5/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
MAPT P10636 2/20 0.40
MEN1 O00255 1/20 0.40
MITF O75030 1/20 0.40
GAA P10253 1/20 0.40
GFER P55789 1/20 0.40
KMT2A Q03164 1/20 0.40
NLRP1 Q9C000 1/20 0.40
NOD2 Q9HC29 1/20 0.40
CYP3A4 P08684 1/20 0.39
TSHR P16473 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
MAPK1 P28482 1/20 0.37
MAOA P21397 2/20 0.35
ABCC8 Q09428 1/20 0.34
KCNJ11 Q14654 1/20 0.34
TEAD4 Q15561 1/20 0.34
MAOB P27338 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2811105 0.99 GRIA2 (0.40) GRIA2ALDH1A1SMN1; SMN2MAPTMEN1
SCHEMBL1967915 0.87 GRIA2 (0.53) GRIA2MAOAMAOB
SCHEMBL1977428 0.86 GRIA2 (0.40) GRIA2ALDH1A1ABCC8KCNJ11
SCHEMBL1971790 0.86 GRIA2 (0.40) GRIA2MEN1KMT2A
SCHEMBL29451639 0.84 ABCC8 (0.43) ALDH1A1SMN1; SMN2MAPTMEN1GAA
SCHEMBL1970202 0.83 ALDH1A1 (0.40) GRIA2ALDH1A1SMN1; SMN2MAPTMEN1
Hydrochloric Acid SCHEMBL2811108 0.82 ALDH1A1 (0.39) GRIA2ALDH1A1SMN1; SMN2MAPTMEN1
SCHEMBL1980510 0.82 VEGFA (0.45) GRIA2
SCHEMBL1982798 0.82 ADAM17 (0.46) GRIA2ALDH1A1SMN1; SMN2MAPTMEN1
SCHEMBL1979031 0.80 GRIA2 (0.41) GRIA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8236790-B2 Benzothiadiazepine compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATORIES SERVIER (FR) 2012-08-07 US claimed
EP-2246339-B1 Derivatives of benzothiazepine and their use as modulators of AMPA and NMDA receptors SERVIER LAB (FR) 2011-06-22 EP claimed
EP-2246339-A1 Derivatives of benzothiazepine and their use as modulators of AMPA and NMDA receptors Les Laboratoires Servier (FR) 2010-11-03 EP claimed
US-20100240635-A1 Benzothiadiazepine compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2010-09-23 US claimed
US-8236790-B2 Benzothiadiazepine compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATORIES SERVIER (FR) 2012-08-07 US disclosed
EP-2246339-B1 Derivatives of benzothiazepine and their use as modulators of AMPA and NMDA receptors SERVIER LAB (FR) 2011-06-22 EP disclosed
EP-2246339-A1 Derivatives of benzothiazepine and their use as modulators of AMPA and NMDA receptors Les Laboratoires Servier (FR) 2010-11-03 EP disclosed
US-20100240635-A1 Benzothiadiazepine compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2010-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240635-A1 Benzothiadiazepine compounds, a process for their preparation and pharmaceutical compositions containing them GRIN1, GRIN2B, GRIN3A GRIA2 45/4885ALDH1A1 2046/4885SMN1; SMN2 3586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.